NEW YORK (AP) - Johnson & Johnson said Friday that European Union regulators approved a pill that combines its diabetes drug Invokana with metformin, an older treatment for the disease.
Janssen-Cilag International will market the drug under the name Vokanamet. It is intended to treat type 2 diabetes, in which the body does not use insulin efficiently.
The U.S. Food and Drug Administration approved Invokana in March 2013. European Union authorities followed suit in November.
People were interested in these podcasts
Shares of Johnson & Johnson lost 19 cents to $99.77 in midday trading.
Please read our comment policy before commenting.